Delivery Order SPE2DB20D1109-SPE2DB23FN39A
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $80,622.65 firm fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product, with a completion date of September 23, 2021. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract, valued at $13,490.07, is for the delivery of Pulmozyme, a 1 mg/ml medication for the treatment of cystic fibrosis, in 2.5 ml ampules. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award, valued at $15,441.37, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to support the healthcare needs of military personnel and veterans. The award is not designated as a set-aside contract. It is a delivery order issued under Amerisourcebergen's Indefinite Delivery...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery order of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication, with a ceiling value of $76,001.44 and a completion date of February 11, 2025. The contract is a firm fixed-price delivery order, which is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the...
- This contract award, valued at $34,586.02, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a specialty pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for...
- This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampuls, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $7,941.03 and an ultimate completion date of October 12, 2023. It is a Firm Fixed Price Delivery Order contract, without any set-aside designation. Amerisourcebergen...
- This federal contract award, valued at $3,476.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a completion date of February 20, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
- This federal contract award SPE2DX15D3017|SPE2DX24F0KWQ, valued at $12,070.46, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of March 7, 2024. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract has a ceiling value of $19,443.25 and is a firm fixed-price delivery order, with an ultimate completion date of April 7, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is a delivery order valued at $2,540.23, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of February 9, 2024. The contract type is firm fixed price. Amerisourcebergen Drug Corp is an established prime contractor providing a wide range of pharmaceutical products and medical supplies...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB23FN39ADelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of 4559695164 - PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a ceiling value of $5,734.70 and an ultimate completion date of January 25, 2023. The parent IDC held by Cencora, Inc. is valued at up to $999,999,999.00 and runs through December 31, 2025, serving as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. This contract award was made through full and open competition without any set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 1/24/23 |